Visual improvement following continuous positive airway pressure therapy in diabetic subjects with clinically significant macular oedema and obstructive sleep apnoea: Proof of principle study

Respiration

Volumn 84, Issue 4, 2012, Pages 275-282

  Mason, Rebecca H ^a,b   Kiire, Christine A ^c   Groves, Dawn C ^c   Lipinski, Helen J ^c   Jaycock, Alyson ^c   Winter, Barbara C ^b   Smith, Lewis ^c   Bolton, Anne ^c   Rahman, Najib M ^b   Swaminathan, R ^d   Chong, Victor N ^c   Stradling, John R ^b  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c OXFORD EYE HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Clinically significant macular oedema; Diabetes; Obstructive sleep apnoea; Retinopathy; Visual acuity

Indexed keywords

HEMOGLOBIN A1C; MESSENGER RNA; RHODOPSIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DISEASE DURATION; EPWORTH SLEEPINESS SCALE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; OXYGEN SATURATION; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

AGED; CONTINUOUS POSITIVE AIRWAY PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; RETINA; SLEEP APNEA, OBSTRUCTIVE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84867040695     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000334090     Document Type: Article

References (26)

1. Parravano M, Menchini F, Virgili G: Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009;(4):CD007419.
2. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ: Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204-210.
3. West SD, Nicoll DJ, Stradling JR: Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006; 61: 945-950.
4. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
5. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL: Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002; 165: 677-682.
6. Meslier N, Gagnadoux F, Giraud P, Person C, Ouksel H, Urban T, Racineux JL: Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. Eur Respir J 2003; 22: 156-160.
7. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-741.
8. Marin JM, Carrizo SJ, Vicente E, Agusti AG: Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
9. Mason RH, Ruegg G, Perkins J, Hardinge M, Amann-Vesti B, Senn O, Stradling JR, Kohler M: Obstructive sleep apnea in patients with abdominal aortic aneurysms: highly prevalent and associated with aneurysm expansion. Am J Respir Crit Care Med 2011; 183: 668-674.
10. Büchner NJ, Quack I, Woznowski M, Stähle C, Wenzel U, Rump LC: Microvascular endothelial dysfunction in obstructive sleep apnea is caused by oxidative stress and improved by continuous positive airway pressure therapy. Respiration 2011; 82: 409-417.
11. Lavie L, Polotsky V: Cardiovascular aspects in obstructive sleep apnea syndrome-molecular issues, hypoxia and cytokine profiles. Respiration 2009; 78: 361-370.
12. Idris I, Hall AP, O'Reilly J, Barnett A, Allen M, Andrews R, Grunstein P, Lewis K, Goenka N, Wilding JP: Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. Diabetes Obes Metab 2009; 11: 733-741.
13. Shiba T, Sato Y, Takahashi M: Relationship between proliferative diabetic retinopathy and sleep-disordered breathing (in Japanese). Nippon Ganka Gakkai Zasshi 2007; 111: 899-904.
14. Mason RH, West SD, Chong V, Stradling JR: Sleep apnoea in 58 patients with diabetic macular oedema. Thorax 2010; 64:A13.
15. Erman MK, Stewart D, Einhorn D, Gordon N, Casal E: Validation of the ApneaLink for the screening of sleep apnea: a novel and simple single-channel recording device. J Clin Sleep Med 2007; 3: 387-392.
16. Chen H, Lowe AA, Bai Y, Hamilton P, Fleetham JA, Almeida FR: Evaluation of a portable recording device (ApneaLink) for case selection of obstructive sleep apnea. Sleep Breath 2009; 13: 213-219.
17. Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, Kohner E, Scanlon P, Leese G: Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med 2003; 20: 965-971.
18. Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C: Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007; 114: 1520-1525.
19. Hamaoui K, Butt A, Powrie J, Swaminathan R: Concentration of circulating rhodopsin mRNA in diabetic retinopathy. Clin Chem 2004; 50: 2152-2155.
20. Wong A, Merritt S, Butt AN, Williams A, Swaminathan R: Effect of hypoxia on circulating levels of retina-specific messenger RNA in type 2 diabetes mellitus. Ann NY Acad Sci 2008; 1137: 243-252.
21. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
22. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA: Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
23. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL III, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
24. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH: Relationship between optical coherence tomographymeasured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525-536.
25. Arden GB, Sidman RL, Arap W, Schlingemann RO: Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764-769.
26. Kohler M, Pepperell JC, Casadei B, Craig S, Crosthwaite N, Stradling JR, Davies RJ: CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J 2008; 32: 1488-1496.